Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 10/20 | 0.62 |
| ▸ | DGAT1 | O75907 | 9/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15471467 | 1.00 | FFAR1 (0.62) | FFAR1DGAT1FFAR4CYP2C8CYP2C9 | |
| SCHEMBL23952772 | 0.93 | FFAR1 (0.56) | FFAR1DGAT1FFAR4CYP2C8CYP2C9 | |
| SCHEMBL16845976 | 0.93 | FFAR1 (0.56) | FFAR1DGAT1FFAR4CYP2C8CYP2C9 | |
| SCHEMBL18963536 | 0.93 | FFAR1 (0.56) | FFAR1DGAT1FFAR4CYP2C8CYP2C9 | |
| SCHEMBL19670781 | 0.93 | FFAR1 (0.56) | FFAR1DGAT1FFAR4CYP2C8CYP2C9 | |
| SCHEMBL15465281 | 0.92 | FFAR1 (0.54) | FFAR1DGAT1FFAR4CYP2C8CYP2C9 | |
| SCHEMBL15471471 | 0.92 | FFAR1 (0.54) | FFAR1DGAT1FFAR4CYP2C8CYP2C9 | |
| SCHEMBL22474739 | 0.90 | FFAR1 (0.56) | FFAR1DGAT1FFAR4CYP2C8CYP2C9 | |
| SCHEMBL15465404 | 0.90 | FFAR1 (0.58) | FFAR1DGAT1FFAR4CYP2C8CYP2C9 | |
| SCHEMBL15471480 | 0.90 | FFAR1 (0.56) | FFAR1DGAT1FFAR4CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2880028-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-09-30 | — | — | EP | disclosed |
| US-9527875-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150191495-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2015-07-09 | — | — | US | disclosed |
| US-20140045746-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045746-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR52 | FFAR1 19/4885DGAT1 104/4885FFAR4 8/4885 |
| US-20150191495-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR52 | FFAR1 19/4885DGAT1 104/4885FFAR4 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.